1. American Headache Society . The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019; 59: 1–18.
Google Scholar2. Smelt, AF, Louter, MA, Kies, DA, et al. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? Results of a Delphi study. PLoS One 2014; 9: e98933.
Google Scholar | Crossref | Medline3. Ferrari, MD, Goadsby, P, Roon, K, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633–658.
Google Scholar | SAGE Journals | ISI4. Dodick, DW. Triptan non-responder studies: Implications for clinical practice. Headache 2005; 45: 156–162.
Google Scholar | Crossref | Medline | ISI5. Sheftell, F, Almas, M, Weeks, R, et al. Quantifying the return of headache in triptan-treated migraineurs: An observational study. Cephalalgia 2010; 30: 838–846.
Google Scholar | SAGE Journals | ISI6. Landy, SH, Tepper, SJ, Schweizer, E, et al. Outcome for headache and pain-free non-responders to treatment of the first attack: A pooled post-hoc analysis of four randomized trials of eletriptan 40 mg. Cephalalgia 2014; 34: 376–381.
Google Scholar | SAGE Journals | ISI7. Messali, AJ, Yang, M, Gillard, P, et al. Treatment persistence and switching in triptan users: A systematic literature review. Headache 2014; 54: 1120–1130.
Google Scholar | Crossref | Medline8. Wells, RE, Markowitz, SY, Baron, EP, et al. Identifying the factors underlying discontinuation of triptans. Headache 2014; 54: 278–289.
Google Scholar | Crossref | Medline9. Lombard, L, Farrar, M, Ye, W, et al. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain 2020; 21: 1–16.
Google Scholar | Crossref | Medline10. Lipton, RB, Fanning, KM, Serrano, D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 2015; 84: 688–695.
Google Scholar | Crossref | Medline | ISI11. Lipton, RB, Reed, ML, Kurth, T, et al. Framingham‐based cardiovascular risk estimates among people with episodic migraine in the US population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2017; 57: 1507–1521.
Google Scholar | Crossref | Medline12. Buse, DC, Reed, ML, Fanning, KM, et al. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2017; 57: 31–44.
Google Scholar | Crossref | Medline13. GlaxoSmithKline . Imitrex (sumatriptan succinate) (package insert). Research Triangle Park, NC: GlaxoSmithKline, https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Imitrex_Tablets/pdf/IMITREX-TABLETS-PI-PIL.PDF (2017, accessed 14 July 2021).
Google Scholar14. Kuca, B, Silberstein, SD, Wietecha, L, et al. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology 2018; 91: e2222–e2232.
Google Scholar | Crossref | Medline15. Goadsby, PJ, Wietecha, LA, Dennehy, EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 2019; 142: 1894–1904.
Google Scholar | Crossref | Medline16. Knievel, K, Buchanan, AS, Lombard, L, et al. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans. Cephalalgia 2020; 40: 19–27.
Google Scholar | SAGE Journals | ISI17. Ashina, M, Reuter, U, Smith, T, et al. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia 2021; 41: 294–304.
Google Scholar | SAGE Journals | ISI18. Diener, HC, Ashina, M, Durand-Zaleski, I, et al. Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. Cephalalgia 2021; 41: 279–293.
Google Scholar | SAGE Journals | ISI19. Diener, H-C, Tassorelli, C, Dodick, DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults. Cephalalgia 2019; 39: 687–710.
Google Scholar | SAGE Journals | ISI20. Dodick, DW, Turkel, CC, DeGryse, RE, et al. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain 2015; 16: 164–175.
Google Scholar | Crossref | Medline | ISI21. Dodick, DW, Shewale, AS, Lipton, RB, et al. Migraine patients with cardiovascular disease and contraindications: An analysis of real-world claims data. J Primary Care Community Health 2020; 11: 2150132720963680.
Google Scholar | SAGE Journals | ISI22. Bretz, F, Maurer, W, Brannath, W, et al. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009; 28: 586–604.
Google Scholar | Crossref | Medline | ISI23. Nelson, DL, Phebus, LA, Johnson, KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010; 30: 1159–1169.
Google Scholar | SAGE Journals | ISI24. Labastida-Ramírez, A, Rubio-Beltrán, E, Haanes, KA, et al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain 2020; 161: 1092.
Google Scholar | Crossref | Medline25. Rubio-Beltrán, E, Labastida-Ramírez, A, Villalón, CM, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Therapeut 2018; 186: 88–97.
Google Scholar | Crossref | Medline